Hypotriglyceridemic action of omega-3 fatty acids in healthy subjects does not occur by enhanced lipoprotein lipase and hepatic lipase activities.
Single blind administration of EPA-rich omega-3 fatty acids at 3 dose levels of 3g, 6g and 12g/d (each dose lasting 3 weeks was separated by 2 weeks on placebo) lowered plasma TG levels and lecithin cholesterol acyltransferase-molar esterification rate (LCAT-MER) activity (6.12g/d). Lipolytic enzymes activity (LPL and HL) remained unchanged at these doses. Fat malabsorption was unlikely because of unmodified plasma beta-carotene, retinol and alpha-tocopherol levels.
Desager
J P
JP
Laboratoire de Pharmacothérapie-Université Catholique de Louvain, Brussels, Belgium.
Dricot
J
J
Harvengt
C
C
D000328:Adult; D001059:Apoproteins / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008049:Lipase / Q000378:metabolism*; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000097:blood; D008099:Liver / Q000201:enzymology*; D008297:Male; D010743:Phospholipids / Q000097:blood; D014280:Triglycerides / Q000097:blood*; D014801:Vitamin A / Q000097:blood; D014810:Vitamin E / Q000097:blood
D001059:Apoproteins; D008076:Cholesterol, HDL; D015525:Fatty Acids, Omega-3; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D010743:Phospholipids; D014280:Triglycerides; D014801:Vitamin A; D014810:Vitamin E; D008049:Lipase; D008071:Lipoprotein Lipase